Lowdose ritonavirboosted darunavir once daily versus ritonavirboosted lopinavir for participants with less than 50 HIV RNA copies per MlWRHI 052 a randomised openlabel phase 3 noninferiority trial

dc.citation.doi10.1016/S2352-3018(19)30081-5
dc.citation.epage437
dc.citation.spage428
dc.contributor.authorWillem Venter
dc.contributor.authorMichelle Moorhouse
dc.contributor.authorSimiso Sokhela
dc.contributor.authorCelicia Serenata
dc.contributor.authorGodspower Akpomiemie
dc.contributor.authorAmbar Qavi
dc.contributor.authorNonkululeko Mashabane
dc.contributor.authorNatasha Arulappan
dc.contributor.authorJoel Weibo Sim
dc.contributor.authoret al et al
dc.contributor.authorTom Boyles
dc.contributor.authorSarah Stacey
dc.date.accessioned2023-10-06T12:02:14Z
dc.date.available2023-10-06T12:02:14Z
dc.identifier.citationISI
dc.identifier.issn2352-3018
dc.identifier.urihttps://hdl.handle.net/10539/36419
dc.journal.titleLANCET HIV
dc.journal.volume6
dc.titleLowdose ritonavirboosted darunavir once daily versus ritonavirboosted lopinavir for participants with less than 50 HIV RNA copies per MlWRHI 052 a randomised openlabel phase 3 noninferiority trial
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Journal.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format
Description:
Journal